Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Blake A. Jacobson
Resistance to EGFR-TKI Can Be Mediated Through Multiple Signaling Pathways Converging Upon Cap-Dependent Translation in EGFR-Wild Type NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P009 to Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC With Wild-Type EGFR
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
Molecular Cancer Therapeutics
Cancer Research
Oncology
Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC
Lung Cancer Management
Cabozantinib Is More Effective Than Erlotinib in EGFR –Wild-Type NSCLC
Cancer Discovery
Oncology
Urea Cycle Sustains Cellular Energetics Upon EGFR Inhibition in EGFR Mutant NSCLC
Molecular Cancer Research
Cancer Research
Oncology
Molecular Biology
Shikonin Sensitizes Wild‑type EGFR NSCLC Cells to Erlotinib and Gefitinib Therapy
Molecular Medicine Reports
Oncology
Genetics
Molecular Biology
Biochemistry
Cancer Research
Molecular Medicine
MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
Expert Review of Anticancer Therapy
Oncology
Pharmacology
